Archive for the 'Mesothelioma Blood Test' Category

Mesothelioma Blood Test news feed.

Metal-based Compound May Reduce Tumor Size in Pleural, Peritoneal Mesothelioma

Mesothelial cells are found in the lining of major organs such as the chest or the abdomen. When asbestos fibers are inhaled or ingested, they slice through the soft tissue and become embedded in the lining of these organs. These fibers cause genetic mutations in the mesothelial cells which then cause the cells to reproduce

more

Calretinin More Effective Than Mesothelin in Detecting Mesothelioma Early

Mesothelioma is a rare and aggressive cancer that is difficult to diagnose because symptoms often mimic other diseases such as pulmonary fibrosis or lung cancer. Pathology reports and biopsies help distinguish this cancer from other illnesses, but often patients will have already developed more serious symptoms because the cancer has spread by the time it

more

New research suggests earlier mesothelioma diagnosis is a possibility

Those familiar with the asbestos-caused cancer mesothelioma are well aware the disease takes decades to develop and by the time it’s recognized, it’s too late for recovery.  When symptoms finally develop and mesothelioma is diagnosed, its victims often survive less than one year. In 2008, Japanese researchers released a study about a protein produced by

more

Gene Expression Ratio Test Predicts Post-Surgery Outcome in Mesothelioma

A four-gene expression ratio test prospectively distinguished mesothelioma patients who had a statistically significant longer overall survival from those who had shorter survival, according to researchers from the Brigham and Women’s Hospital. The team’s previous retrospective studies found that measuring expression ratios of four genes could distinguish between those who have a good prognosis after

more

Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso

Rosetta Genomics, Ltd. (NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the introduction of its third diagnostic test, miRview(TM) meso. The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia. To order the test, physicians may contact 1-888-522-7971, or visit the company’s website http://www.rosettagenomics.com. "I am very excited to

more

Fujirebio Diagnostics Honored with Pioneer Award from Meso Foundation: MESOMARK® Test Recognized for Monitoring Patients with Asbestos-linked Cancer

Malvern, PA – Noting a steadfast dedication and contribution to researching mesothelioma, an asbestos-linked cancer, the Meso Foundation recently bestowed a Pioneer Award to Fujirebio Diagnostics. The company, whose MESOMARK® test was introduced earlier this year, was presented with the award at the Meso Foundation’s annual International Symposium on Malignant Mesothelioma. MESOMARK is the world’s

more

NYU Medical Center Partners With Rosetta Genomics to Develop a Line of Diagnostic Tools for Lung and Mesothelioma Cancers

Rosetta Genomics, Ltd. (NASDQ: ROSG) announced today that it has partnered with NYU Medical Center with the aim of developing a line of early detection diagnostic products for lung, and Mesothelioma cancers. The early detection test will mainly target over 45 million Americans who are at an increased risk of lung cancer due to smoking,

more

CISBIO Announces FDA Approval of MESOMARK®; Assay Now Available to Physicians in the U.S. for Monitoring Patients with Mesothelioma

CISBIO, a developer and marketer of diagnostic assays for the quantification of tumor markers, announced that the MESOMARK® Assay, the world’s first in vitro test for managing patients with mesothelioma, an aggressive and deadly form of cancer, has been approved by the United States Food and Drug Administration (FDA). The MESOMARK® test is developed and

more

NYU Study Validates Use Of Fujirebio Diagnostics’ MESOMARK Test For Monitoring An Asbestos-Linked Cancer

There is new hope for the thousands of Americans suffering from mesothelioma, an aggressive form of cancer linked to asbestos exposure. Results from a recent study conducted by researchers at New York University (NYU) School of Medicine show the MESOMARK Assay, the world’s first and only in vitro test for monitoring mesothelioma developed by Fujirebio

more

Elevated Blood Levels of a Protein are Linked to Asbestos-induced Cancers

Researchers at New York University School of Medicine and Wayne State University have found a molecule that reveals the early stages of pleural mesothelioma, a chest cancer caused by asbestos. The finding opens the way to a blood test for the disease, according to a new study published in the Oct. 13 issue of The

more

New Study Shows Promise in a Finding a Blood Test to Detect Mesothelioma

Study results published in the October 13 issue of The New England Journal of Medicine (Asbestos Exposure, Pleural Mesothelioma, and Serum Osteopontin Levels) point to the possibility of a blood test to detect mesothelioma in its early stages. Mesothelioma, a rare cancer caused by asbestos exposure, has an average survival time after diagnosis of nine

more

Ground-Breaking Mesothelioma Detection Study Begins – Libby, MT Residents Participating in Mesothelioma Applied Research Foundation (MARF) Funded Research into Mesothelioma Serum Marker

Exciting new developments using a blood serum marker to detect cancer are being investigated in a longitudinal study in Libby, Montana. In a generous and caring humanitarian act, nearly half of Libby, Montana residents, many of whom have been exposed to asbestos, have agreed to participate in a long term study to calibrate a newly

more

Fujirebio Diagnostics Expands Commercial Availability of First Blood Test for Mesothelioma: Announces Distribution Agreement with Cisbio international to Bring MESOMARK™ to Europe

Fujirebio Diagnostics, Inc. (FDI), a world-leader in oncology testing, and Cisbio international, a French biotechnology company, today announced a distribution agreement for European distribution of FDI’s new blood test for mesothelioma – MESOMARK™. This agreement, the second for FDI, continues the worldwide commercial rollout of MESOMARK. Earlier this year, FDI launched MESOMARK in Australia where

more

Fujirebio Diagnostics Launches First Blood Test for Mesothelioma: Vital Diagnostics to Make Test Commercially Available in Australia

Fujirebio Diagnostics, Inc. (FDI), a world-leader in oncology testing, today announced that it has signed a distributor agreement with Australian-based Vital Diagnostics for its new blood test for mesothelioma – MESOMARK TM. The agreement marks the beginning of the company’s commercial roll-out of MESOMARK, which is now available for the first time in Australia. "The

more

Asbestos cancer breakthrough: First-ever blood test for mesothelioma being developed

Source: Eureka Alert November 13, 2003. Seattle–Researchers at the Pacific Northwest Research Institute (PNRI) have reported the development of a blood test for mesothelioma, a highly aggressive lung cancer caused by asbestos exposure. A PNRI team led by Dr. Ingegerd Hellstrom, and an Australian team, led by Dr. Bruce Robinson, of the University of Western

more

Last update: March 06, 2014. 08:41:31 pm.